Snapshot:
- Agentic RTSM at Suvoda reduces kickoff-to-UAT timelines by up to 80%. Not by cutting corners, but by changing where skilled effort is applied.
- AI agents handle configuration, customization, and testing. Each phase runs iteratively within an architecture that keeps validated core code untouched.
- Speed in a regulated environment requires accountability. Every step in an agentic build is auditable, and compliance is structural rather than layered on after the fact.
Getting a clinical trial off the ground is a coordination challenge that runs on many tracks at once. Contract negotiations. Site identification and qualification. Ethics committee reviews. Regulatory submissions. Patient recruitment strategy. Each of these demands real attention from experienced people—the kind of judgment-intensive work that shapes whether a study enrolls well and runs smoothly.
RTSM configuration has always been one more track running alongside all of this. Important, detailed work—but work that, until recently, has claimed too much of sponsors' time and attention during a period when that time is already stretched.
Where the build actually begins
Traditionally, the first major phase of an RTSM build is requirements gathering. Before any of the system build can start, sponsors and technology teams spend weeks working through documentation: defining how the technology needs to reflect the study design—countries, cohort structures, visit schedules, randomization parameters, workflows. In the typical model, this process produces a User Requirements Specification, a document that is thorough by necessity and demanding to produce. This process is time consuming and requires the attention of the sponsor team, who are simultaneously managing every other aspect of the study.
Agentic RTSM—the next evolution of the industry-leading Suvoda IRT—simplifies the requirements gathering. With Agentic RTSM, Suvoda can produce a Study Design Package based on study information the sponsor provides during kickoff—a substantially shorter, more focused input that captures what the build needs without the overhead of a full specification process. The same rigor flows into the build; the burden on sponsor and Suvoda teams to produce it is considerably lighter.
What the build contains—and what changes
In the traditional model, after the sponsor signs off on the URS, the build itself follows a familiar sequence: core system configuration, study-specific customization, and testing. Each step requires skilled human effort to execute—careful, expert, and time intensive by design.
Agentic RTSM runs that sequence differently. After the sponsor signs off on the Study Design Package, a family of purpose-built AI agents—with Suvoda experts in the lead—handles each part iteratively: Study XD agent for core configuration, Customize XD agent for study-specific adaptations, Test XD agent for testing cycles. Countries, visits, cohort structures, randomization schemes, and workflows are configured by agents working within the Suvoda Platform's patented Virtual Partition architecture—so agents can only change study-specific specifications, never the validated core code.
Suvoda's services experts remain central throughout. They shape what the agents do, review outputs, and refine the build through iterative cycles with the sponsor team. The expertise has not changed. Where it is applied has.
The result is a reduction in the kickoff-to-UAT timeline of up to 80%. And when a protocol changes, study amendments are a controlled, speedy process, not a project themselves.
Built for a regulated environment
Speed in a regulated context requires accountability. Every step in an agentic RTSM build is auditable. The Suvoda Platform's architecture is designed so that validated core code does not change—agents work only on what is unique to a given study. Those study specific changes are separately tested by Test XD agents, logging all evidence to meet compliance requirements. Compliance is not a feature layered on after the fact; it is structural.
At UAT, the system and its documentation reflect exactly what the sponsor and Suvoda's services team reviewed and refined together. The process is faster, but it is not a black box.
What that shift is actually worth
A faster technology build does not, on its own, move first patient in earlier—RTSM is one workstream among many that need to complete before enrollment begins. But it changes how sponsors experience that window.
When the technology track moves faster and demands less, the attention it was consuming is available elsewhere. For the site selection work that benefits from focused effort. For the patient recruitment strategy that shapes how well the study enrolls. For the regulatory coordination that demands thoughtful attention. For the IRB approvals that cannot be rushed but can be better prepared for.
The value of agentic RTSM is not only a number on a timeline. It is what happens when sponsors and their teams are no longer spending the startup period managing a technology build—and can instead focus on the parts of study startup that require their judgment most.
That shift is worth having a conversation about, wherever your next study is.